These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

568 related articles for article (PubMed ID: 19421058)

  • 61. [Epidemiology and therapy of infections caused by Neisseria meningitidis].
    Skoczyńska A; Hryniewicz W
    Pol Merkur Lekarski; 2003 Nov; 15(89):459-62. PubMed ID: 14969144
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Clinical aspects and outcome of meningococcal disease due to Neisseria meningitidis of serogroup W135 in 5 children].
    Faye A; Mariani-Kurkjian P; Taha MK; Louzeau C; Bingen E; Bourrillon A
    Arch Pediatr; 2005 Mar; 12(3):291-4. PubMed ID: 15734127
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Anti-meningococcal vaccines].
    Taha MK; Alonso JM
    Rev Prat; 2008 Dec; 58(19):2099-101. PubMed ID: 19213536
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Protecting the world against meningitis: new recommendations from the CDC's advisory committee on immunization practices.
    Cyrus SS;
    J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S17-9. PubMed ID: 22086889
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt.
    Mueller JE; Gessner BD
    Int J Infect Dis; 2010 Jul; 14(7):e553-9. PubMed ID: 20018546
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, October 2005-February 2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Apr; 55(13):364-6. PubMed ID: 16601664
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci.
    Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Meningococcal disease].
    Haruta T
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():335-8. PubMed ID: 12722239
    [No Abstract]   [Full Text] [Related]  

  • 69. MCV vaccination in the presence of vaccine-associated Guillain-Barré Syndrome risk: a decision analysis approach.
    Cho BH; Clark TA; Messonnier NE; Ortega-Sanchez IR; Weintraub E; Messonnier ML
    Vaccine; 2010 Jan; 28(3):817-22. PubMed ID: 19879992
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years.
    Galloway Y; Stehr-Green P; McNicholas A; O'Hallahan J
    Int J Epidemiol; 2009 Apr; 38(2):413-8. PubMed ID: 18988650
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Characteristics of meningococcal meningitis in children in France].
    Levy C; Taha MK; Weill Olivier C; Quinet B; Lécuyer A; Alonso JM; Cohen R; Bingen E;
    Arch Pediatr; 2008 Dec; 15 Suppl 3():S105-10. PubMed ID: 19268239
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Multicenter surveillance of invasive meningococcal infections in children.
    Kaplan SL; Schutze GE; Leake JA; Barson WJ; Halasa NB; Byington CL; Woods CR; Tan TQ; Hoffman JA; Wald ER; Edwards KM; Mason EO
    Pediatrics; 2006 Oct; 118(4):e979-84. PubMed ID: 17015517
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006.
    Mutonga DM; Pimentel G; Muindi J; Nzioka C; Mutiso J; Klena JD; Morcos M; Ogaro T; Materu S; Tetteh C; Messonnier NE; Breiman RF; Feikin DR
    Am J Trop Med Hyg; 2009 Apr; 80(4):619-24. PubMed ID: 19346388
    [TBL] [Abstract][Full Text] [Related]  

  • 75. In brief: a booster dose of meningococcal vaccine for adolescents.
    Med Lett Drugs Ther; 2011 May; 53(1364):37. PubMed ID: 21566543
    [No Abstract]   [Full Text] [Related]  

  • 76. In brief: prevention of meningococcus B disease.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):97. PubMed ID: 24322662
    [No Abstract]   [Full Text] [Related]  

  • 77. Rapid laboratory detection of meningococcal disease outbreaks caused by serogroup C Neisseria meningitidis.
    Killoran PB; O'Connell J; Mothershed EA; Probert WS
    J Microbiol Methods; 2006 Nov; 67(2):330-8. PubMed ID: 16740329
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Update: Guillain-Barré syndrome among recipients of Menactra meningococcal conjugate vaccine--United States, June 2005-September 2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2006 Oct; 55(41):1120-4. PubMed ID: 17060898
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Morbidity, mortality and spatial distribution of meningococcal disease, 1974-2007.
    Howitz M; Lambertsen L; Simonsen JB; Christensen JJ; Mølbak K
    Epidemiol Infect; 2009 Nov; 137(11):1631-40. PubMed ID: 19327198
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System.
    Ball R; Braun MM; Mootrey GT;
    Clin Infect Dis; 2001 May; 32(9):1273-80. PubMed ID: 11303261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.